http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
22nd Century Group Welcomes Dr. Califf as FDA Commissioner, Urges Action on Menthol and Nicotine in Combustible Cigarettes
-
22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation
-
22nd Century Group (XXII) Secures USDA Organic Certification for Needle Rock Farms
-
22nd Century Secures USDA Organic Certification for Needle Rock Farms
-
22nd Century Group to Announce Fourth Quarter and Full Year 2021 Results on March 1, 2022
-
22nd Century Group Supports Upcoming FDA Action Banning Menthol in Highly Addictive Combustible Cigarettes
-
22nd Century Group (XXII) Announces First Production of VLN® Cigarettes for Retail Sale
-
22nd Century Group Announces First Production of VLN® Cigarettes for Retail Sale
-
22nd Century Group (XXII) Appoints James A. Mish to Its Board
-
22nd Century Group Appoints James A. Mish to Its Board of Directors
-
22nd Century Group (XXII) Says it's Launching First Reduced Nicotine Cigarette Authorized by FDA That Helps You Smoke Less
-
22nd Century Launching the First Reduced Nicotine Cigarette Authorized by the FDA That Helps You Smoke Less
-
22nd Century Group to Participate in Fireside Chat Events with Alliance Global Partners Equity Analyst Aaron Grey and Cowen Equity Analyst Vivien Azer on Wednesday, January 5, 2022
-
22nd Century Group (XXII) Granted FDA Approval for VLN as a Modified Risk Tobacco Product
-
FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product
-
22nd Century Group (XXII) Confirms FDA Authorizes Marketing of its VLN as Modified Risk Tobacco Product
-
FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product
-
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
-
22nd Century Ready to Provide Full Commercial Support to New Zealand’s Plan to Reduce Nicotine Content of All Cigarettes
-
22nd Century Group (XXII) Announces CFO Transition
-
22nd Century Group Announces CFO Transition
-
22nd Century Group Applauds Califf Nomination as FDA Commissioner
-
22nd Century to Participate in Cowen and Roth Capital Investor Conferences in November 2021
-
22nd Century Group Reports Business Highlights and Financial Results for the Third Quarter 2021
-
22nd Century Group to Host Webcast to Provide Business Update and Discuss Third Quarter 2021 Results
-
22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate
-
22nd Century to Participate in the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
-
22nd Century to Participate in September and October 2021 Investor Conferences
-
22nd Century Group Enters Global Specialty Hops Market
-
22nd Century Group (XXII) Appoints Anthony Johnson to its Board
-
22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors
-
22nd Century to Present at SNN Network Investor Conference on August 19
-
22nd Century Group to Ring Nasdaq Closing Bell Today, August 16
-
22nd Century Group to Begin Trading on Nasdaq on August 16, 2021
-
22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021
-
22nd Century Group (XXII) Secures New Contract Manufacturing Agreements, Expands Distribution Network and Manufacturing Capabilities Ahead of VLN Launch
-
22nd Century Group Secures New Contract Manufacturing Agreements, Expands Distribution Network and Manufacturing Capabilities Ahead of VLN® Launch
-
22nd Century Group to Host Webcast to Provide Business Update and Discuss Second Quarter 2021 Results
-
22nd Century Group Adds Strategic Partnerships With Sawatch Agriculture and Folium Botanical for Next-Generation Commercial Hemp/Cannabis Plant Breeding and Commercial Scale-Up
-
22nd Century Group (XXII) Announces Restructuring of Panacea Investment, Expansion of Cannabis Franchise Capabilities
-
22nd Century Announces Restructuring of Panacea Investment, Expansion of Cannabis Franchise Capabilities
-
22nd Century Group (XXII) Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives
-
22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives
-
22nd Century Announces Closing of $40 Million Common Stock Registered Direct Offering
-
Reduced Nicotine Tobacco and Cannabinoid Innovator 22nd Century Group to Be Added to Russell 2000®, Russell 3000®, and Russell Global Indexes
-
22nd Century Group (XXII) Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise
-
22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise
-
22nd Century Group (XXII) Announces $40 Million Common Stock Registered Direct Offering
-
22nd Century Announces $40 Million Common Stock Registered Direct Offering
-
22nd Century to Participate in May and June 2021 Investor Conferences
